For Eli Lilly and Company [LLY], Analyst sees a rise to $222. What next?

Eli Lilly and Company [NYSE: LLY] surged by $4.61 during the normal trading session on Wednesday and reaching a high of $193.57 during the day while it closed the day at $192.81. The company report on May 5, 2021 that Lilly to Participate in Bank of America Securities 2021 Health Care Conference.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2021 Health Care Conference on Tuesday, May 11, 2021. Michael Mason, senior vice president, president of Lilly Diabetes, will participate in a virtual fireside chat at 9:30 a.m., Eastern Time.

A live audio webcast will be available on the “Webcasts & Presentations” section of Lilly’s Investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.

Eli Lilly and Company stock has also gained 6.79% of its value over the past 7 days. However, LLY stock has declined by -2.11% in the 3 months of the year. Over the past six months meanwhile, it has gained 46.48% and gained 14.20% year-on date.

The market cap for LLY stock reached $184.33 billion, with 908.04 million shares outstanding and 856.60 million shares in the current float. Compared to the average trading volume of 3.48M shares, LLY reached a trading volume of 4271610 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Eli Lilly and Company [LLY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LLY shares is $212.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LLY stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Mizuho have made an estimate for Eli Lilly and Company shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 19, 2021. While these analysts kept the previous recommendation, Wolfe Research raised their target price from $147 to $183. The new note on the price target was released on December 10, 2020, representing the official price target for Eli Lilly and Company stock. Previously, the target price had yet another raise to $150, while Bernstein analysts kept a Mkt Perform rating on LLY stock.

The Average True Range (ATR) for Eli Lilly and Company is set at 3.49, with the Price to Sales ratio for LLY stock in the period of the last 12 months amounting to 7.23. The Price to Book ratio for the last quarter was 31.05, with the Price to Cash per share for the same quarter was set at 3.85. Price to Free Cash Flow for LLY in the course of the last twelve months was 66.21 with Quick ratio for the last quarter at 1.10.

LLY stock trade performance evaluation

Eli Lilly and Company [LLY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.79. With this latest performance, LLY shares gained by 5.48% in over the last four-week period, additionally plugging by 46.48% over the last 6 months – not to mention a rise of 22.12% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LLY stock in for the last two-week period is set at 60.05, with the RSI for the last a single of trading hit 67.12, and the three-weeks RSI is set at 55.97 for Eli Lilly and Company [LLY]. The present Moving Average for the last 50 days of trading for this stock 190.61, while it was recorded at 186.38 for the last single week of trading, and 168.49 for the last 200 days.

Eli Lilly and Company [LLY]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Eli Lilly and Company [LLY] shares currently have an operating margin of +27.91 and a Gross Margin at +77.66. Eli Lilly and Company’s Net Margin is presently recorded at +25.24.

Return on Total Capital for LLY is now 33.38, given the latest momentum, and Return on Invested Capital for the company is 31.65. Return on Equity for this stock inclined to 150.18, with Return on Assets sitting at 14.42. When it comes to the capital structure of this company, Eli Lilly and Company [LLY] has a Total Debt to Total Equity ratio set at 294.16. Additionally, LLY Total Debt to Total Capital is recorded at 74.63, with Total Debt to Total Assets ending up at 35.59. Long-Term Debt to Equity for the company is recorded at 294.01, with the Long-Term Debt to Total Capital now at 74.59.

Reflecting on the efficiency of the workforce at the company, Eli Lilly and Company [LLY] managed to generate an average of $176,963 per employee. Receivables Turnover for the company is 3.94 with a Total Asset Turnover recorded at a value of 0.57.Eli Lilly and Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.40.

Earnings per share (EPS) analysis for Eli Lilly and Company [LLY] stock

With the latest financial reports released by the company, Eli Lilly and Company posted 1.89/share EPS, while the average EPS was predicted by analysts to be reported at 1.56/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LLY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Eli Lilly and Company go to 12.37%.

Eli Lilly and Company [LLY]: Insider Ownership positions

There are presently around $151,432 million, or 83.90% of LLY stock, in the hands of institutional investors. The top three institutional holders of LLY stocks are: LILLY ENDOWMENT INC with ownership of 110,302,100, which is approximately -0.747% of the company’s market cap and around 11.70% of the total institutional ownership; VANGUARD GROUP INC, holding 68,661,494 shares of the stock with an approximate value of $13.24 billion in LLY stocks shares; and BLACKROCK INC., currently with $11.34 billion in LLY stock with ownership of nearly -2.745% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Eli Lilly and Company stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 831 institutional holders increased their position in Eli Lilly and Company [NYSE:LLY] by around 92,043,653 shares. Additionally, 852 investors decreased positions by around 41,269,752 shares, while 314 investors held positions by with 652,079,973 shares. The mentioned changes placed institutional holdings at 785,393,378 shares, according to the latest SEC report filing. LLY stock had 193 new institutional investments in for a total of 3,970,571 shares, while 98 institutional investors sold positions of 2,017,136 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam